Accretropin FDA Approval History
FDA Approved: Yes (Discontinued) (First approved January 23, 2008)
Brand name: Accretropin
Generic name: somatropin (rDNA origin)
Dosage form: Subcutaneous Injection
Treatment for: Pediatric Growth Hormone Deficiency, Turner Syndrome
Marketing Status: Discontinued
Accretropin (somatropin (rDNA origin)) is recombinant human growth hormone indicated for treatment of pediatric patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone, or treatment of short stature associated with Turner Syndrome in pediatric patients whose epiphyses are not closed.
Development timeline for Accretropin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.